Orexigen Therapeutics (OREX) - Contrave outperforming

09:52 EDT 17 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Orexigen Therapeutics: Orexigen’s re-launch of Contrave continues to be successful, with an 18% increase in prescriptions in the United States in Q217 compared to Q117. Importantly, net revenue per unit sold increased 37%, indicating better coverage and less discounting. Outside of the US, progress continues as the product has launched in 17 countries, with another 10-15 expected by Q118, including Germany and Italy. The company has also announced that it has commenced an exploration of strategic transactions as a means to maximize the value creation for shareholders.
ISIN: US6861643020

Original Article: Orexigen Therapeutics (OREX) - Contrave outperforming


More From BioPortfolio on "Orexigen Therapeutics (OREX) - Contrave outperforming"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...